Neoepitopes as cancer immunotherapy targets: key challenges and opportunities

Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma

(2016) Avery D. Posey et al.   IMMUNITY

Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses

(2016) Kelly D Moynihan et al.   NATURE MEDICINE

A large fraction of HLA class I ligands are proteasome-generated spliced peptides

(2016) Juliane Liepe et al.   SCIENCE

Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry

(2016) Michal Bassani-Sternberg et al.   Nature Communications

Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade

(2016) Tavi Nathanson et al.   Cancer Immunology Research

Adjuvants for peptide-based cancer vaccines

(2016) Hiep Khong et al.   Journal for ImmunoTherapy of Cancer

T cell receptor binding affinity governs the functional profile of cancer-specific CD8+T cells

(2015) M. P. Tan et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Dendritic-cell vaccines on the move

(2015) Rachel Lubong Sabado et al.   NATURE

T cell exclusion, immune privilege, and the tumor microenvironment

(2015) J. A. Joyce et al.   SCIENCE

Neoepitopes of Cancers: Looking Back, Looking Ahead

(2015) P. K. Srivastava   Cancer Immunology Research

Consensus nomenclature for CD8+T cell phenotypes in cancer

(2015) Lionel Apetoh et al.   OncoImmunology

Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity

(2014) Fei Duan et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

(2014) Eugene D Kwon et al.   LANCET ONCOLOGY

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

(2014) Matthew M. Gubin et al.   NATURE

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing

(2014) Mahesh Yadav et al.   NATURE

Pathways of Antigen Processing

(2013) Janice S. Blum et al.   Annual Review of Immunology

Therapeutic Dendritic Cell-Based Cancer Vaccines: The State of the Art

(2013) Marius M. Strioga et al.   CRITICAL REVIEWS IN IMMUNOLOGY

T-cell Receptor (TCR)-Peptide Specificity Overrides Affinity-enhancing TCR-Major Histocompatibility Complex Interactions

(2013) David K. Cole et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma

(2013) Nienke van Rooij et al.   JOURNAL OF CLINICAL ONCOLOGY

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

(2013) Tyler R. Simpson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer

(2013) Dung T. Le et al.   JOURNAL OF IMMUNOTHERAPY

At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy

(2013) Andrew M. Intlekofer et al.   JOURNAL OF LEUKOCYTE BIOLOGY

MHC Class I Antigen Processing and Presenting Machinery: Organization, Function, and Defects in Tumor Cells

(2013) P. Leone et al.   JNCI-Journal of the National Cancer Institute

Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion

(2013) Yared Hailemichael et al.   NATURE MEDICINE

MHC Class I-Associated Phosphopeptides Are the Targets of Memory-like Immunity in Leukemia

(2013) M. Cobbold et al.   Science Translational Medicine

Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

(2013) M. J. Selby et al.   Cancer Immunology Research

The cancer antigenome

(2012) Bianca Heemskerk et al.   EMBO JOURNAL

Inefficient exogenous loading of a tapasin-dependent peptide onto HLA-B*44:02 can be improved by acid treatment or fixation of target cells

(2012) Vincent Stroobant et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

(2012) Thomas J. Lynch et al.   JOURNAL OF CLINICAL ONCOLOGY

An overview of sipuleucel-T: Autologous cellular immunotherapy for prostate cancer

(2012) Johnna Wesley et al.   Human Vaccines & Immunotherapeutics

T cell recognition of weak ligands: roles of signaling, receptor number, and affinity

(2011) Lindsay J. Edwards et al.   IMMUNOLOGIC RESEARCH

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

NetCTLpan: pan-specific MHC class I pathway epitope predictions

(2010) Thomas Stranzl et al.   IMMUNOGENETICS

Major histocompatibility complex class I binding predictions as a tool in epitope discovery

(2010) Claus Lundegaard et al.   IMMUNOLOGY

Prediction of epitopes using neural network based methods

(2010) Claus Lundegaard et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity

(2010) Mariola Fotin-Mleczek et al.   JOURNAL OF IMMUNOTHERAPY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

(2009) Karl S. Peggs et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group

(2008) Alessandro Testori et al.   JOURNAL OF CLINICAL ONCOLOGY

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

(2008) Christopher Wood et al.   LANCET

History of Bacillus Calmette-Guerin and Bladder Cancer: An Immunotherapy Success Story

(2007) Harry W. Herr et al.   JOURNAL OF UROLOGY